Breakthrough Oral Molecule Eliminates Kidney Stones and Prevents Renal Failure in Lethal Disease Study

New research shows N-PPG can stop kidney stone formation and restore survival in models of PH2, offering a potential breakthrough for untreatable renal diseases.

By: AXL Media

Published: Apr 3, 2026, 10:59 AM EDT

Source: Information for this report was sourced from Buck Institute for Research on Aging

A Potential Cure for a Rare and Lethal Metabolic Disorder

The discovery of N-PPG offers a significant therapeutic leap for patients suffering from Primary Hyperoxaluria Type 2 (PH2), a rare genetic condition that leads to progressive kidney failure in infants and young adults. Currently, those with PH2 have no approved pharmaceutical options, often leaving liver or kidney transplantation as the only means to extend life. Research published in Kidney International demonstrates that this oral molecule can halt the metabolic chain reaction that produces excess oxalate, effectively preventing the development of stone-laden, injured kidneys that typically characterize the disease.

Serendipitous Collaboration Across Scientific Disciplines

The breakthrough was the result of an unconventional partnership between researchers focused on breast cancer and neurodegenerative diseases. While investigating N-PPG as a potential anti-cancer agent, scientists noticed the molecule triggered a beneficial cellular stress response known as mitohormesis. Further metabolic analysis revealed that the compound was deeply involved in the pathway responsible for oxalate production. This interdisciplinary exchange allowed the team to pivot their focus from oncology and Huntington’s disease toward nephrology, identifying a specific enzyme target that had previously been overlooked in kidney stone research.

Blocking the Source of Toxic Oxalate Production

The treatment works by inhibiting a key enzyme called hydroxyproline dehydrogenase (HYPDH/PRODH2), which resides in the liver and kidney mitochondria. This enzyme catalyzes the first step in breaking down hydroxyproline, an amino acid that eventually generates glyoxylate. In patients with PH2, this process is disrupted, leading to a massive overproduction of oxalate that crystallizes in the kidneys. By cutting off this pathway at its source with N-PPG, the researchers were able to prevent the damaging precipitation of calcium oxalate crystals before they could form stones.